• BioNexus attended a working visit to Tongshu Gene facilities in Shanghai and Changzhou to advance the VitaGuard MRD platform rollout in Southeast Asia.
• Sessions mapped implementation needs, with site visits to Chinese hospitals using VitaGuard commercially supporting BioNexus’s 2026 initial deployment target.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280900PRIMZONEFULLFEED9799214) on July 28, 2026, and is solely responsible for the information contained therein.